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Abstract 
Introduction 
Renal cell carcinomas (RCCs) arise from the renal cortex; many patients with 
RCC are asymptomatic until the disease is either locally advanced and unre-
sectable, or metastatic. To date, nivolumab (Opdivo
®
), a human immuno-
globulin G4 (Ig4) monoclonal antibody directed against programmed death-
1 (PD-1), has not been approved throughout Europe for the treatment of pa-
tients with advanced RCC who did not receive prior treatment. Since April 
2018, nivolumab in combination with ipilimumab (Yervoy
®
) has been ap-
proved in the US for the treatment of patients with intermediate- or poor-
risk advanced RCC who did not receive prior therapy.  
Methodology 
Published and grey literature were identified by searching the CRD Data-
base, Embase, Ovid Medline and PubMed, Internet sites and contacting the 
manufacturer, resulting in 224 references overall. A quality assessment was 
conducted to assess the risk of bias at the study level based on the EU-
netHTA internal validity of randomised controlled trials. To evaluate the 
magnitude of “meaningful clinical benefit” that can be expected from a new 
anti-cancer treatment, the Magnitude of Clinical Benefit Scale developed by 
the European Society for Medical Oncology (ESMO-MCBS) was used. Addi-
tionally, an adapted version (due to perceived limitations) of ESMO-MCBS 
was applied. 
Results from the CheckMate 214 trial 
The CheckMate 214 trial assessed the combination of nivolumab plus ipili-
mumab versus sunitinib (Sutent
®
) monotherapy in patients with previously 
untreated advanced RCC in 1,096 patients (79% of the overall study popula-
tion had intermediate- or poor-risk RCC. Analyses showed that intermedi-
ate- and poor-risk patients who received nivolumab plus ipilimumab showed 
a statistically significant benefit in overall survival (OS) and objective re-
sponse rate (ORR) as compared with sunitinib: the 12-month OS rate was 
80% versus 72%, the 18-month OS rate was 75% versus 60%, with a hazard 
ratio (HR) for death of 0.63 (99.8% CI, 0.44–0.89; p <0.001) and an ORR of 
42% versus 27% (p <0.001) in the respective groups.  Health-related quality 
of life (HRQoL) analyses showed better results in intermediate- and poor-
risk patients treated with nivolumab plus ipilimumab. Median progression-
free survival (PFS) was prolonged with nivolumab plus ipilimumab, whereas 
the difference was not statistically significant. Treatment-related AEs of 
grade 3 or 4 occurred in 46% (nivolumab-plus-ipilimumab group) and 63% 
(sunitinib group) of patients. The number of treatment-related deaths was 
higher in patients receiving nivolumab plus ipilimumab. 
Conclusion 
CheckMate 214 study results show that the combination of nivolumab and 
ipilimumab provides clinical benefit in previously untreated, intermediate- 
and poor-risk patients. However, the high rate of treatment-related AEs has 
to be considered. Moreover, data regarding AEs for intermediate- and poor-
risk patients and, additionally, long-term efficacy and safety data of the 
combination therapy would be of interest. Since CheckMate 214 is the only 
phase III trial providing results of nivolumab plus ipilimumab in untreated 
patients with advanced RCC, more data is needed to evaluate this combina-
tion regimen for first-line therapy.
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to predefined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is nivolumab, ipilimumab and sunitinib? 
A0022 Who manufactures nivolumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has nivolumab received marketing authorisation? 
Health problem and current use 
A0002 What is renal cell carcinoma? 
A0004 What is the natural course of renal cell carcinoma? 
A0006 What are the consequences of renal cell carcinoma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of renal cell carcinoma? 
A0003 What are the known risk factors for renal cell carcinoma? 
A0024 
How is renal cell carcinoma currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is renal cell carcinoma currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of nivolumab on mortality? 
D0006 How does nivolumab affect progression (or recurrence) of renal cell carcinoma? 
D0005 
How does nivolumab affect symptoms and findings (severity, frequency) of renal cell 
carcinoma? 
D0011 What is the effect of nivolumab on patients’ body functions? 
D0012 What is the effect of nivolumab on generic health-related quality of life? 
D0013 What is the effect of nivolumab on disease-specific quality of life? 
Safety 
C0008 How safe is nivolumab in relation to the comparator? 
C0002 Are the harms related to dosage or frequency of applying nivolumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of nivolumab? 
A0021 What is the reimbursement status of nivolumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
 
Generic/Brand name/ATC code:  
Nivolumab/Opdivo
®
/L01XC17 
 
B0001: What is nivolumab, ipilimumab and sunitinib? 
Nivolumab (Opdivo
®
) is a human immunoglobulin G4 (Ig4) monoclonal an-
tibody which is directed against the negative immunoregulatory human cell 
surface receptor programmed death-1 (PD-1), showing immune checkpoint 
inhibitory and antineoplastic activities. Nivolumab binds to the PD-1 recep-
tor, thereby blocking its interaction with programmed cell death ligand 1 
(PD-L1) which is overexpressed on certain cancer cells, and programmed 
cell death ligand 2 (PD-L2) which is primarily expressed on antigen present-
ing cells (APCs). This mechanism leads to the inhibition of T-cell prolifera-
tion and cytokine secretion. By blocking PD-1 binding to PD-L1 and PD-L2 
ligands, nivolumab intensifies T-cell responses, including anti-tumour re-
sponses [2, 3].  
Nivolumab, which is produced in Chinese hamster ovary cells by recombi-
nant deoxyribonucleic acid (DNA) technology is available as a concentrate 
for solution for infusion in vials of 4 mL, 10 mL and 24 ml (each mL con-
tains 10 mg of nivolumab) [2]. The U.S. Food and Drug Administration 
(FDA) recommends administering nivolumab (if given in combination with 
ipilimumab) at a dose of 3 mg/kg intravenously (IV) over 30 minutes, fol-
lowed by ipilimumab at a dose of 1 mg/kg IV over 30 minutes on the same 
day, every three weeks for four doses (induction phase). After completion of 
the combination regimen, the administration of nivolumab as a single agent 
(either 240 mg every two weeks or 480 mg every four weeks IV over 30 
minutes) is recommended until disease progression or unacceptable toxicity 
(maintenance phase) [4].  
Before starting the administration of nivolumab, the use of systemic cortico-
steroids and other immunosuppressants should be avoided, since they could 
potentially interfere with the pharmacodynamic activity. After starting 
nivolumab therapy, systemic corticosteroids and immunosuppressants can 
be used for the treatment of immune-related adverse reactions [2]. 
Ipilimumab (Yervoy
®
) is a human anti-cytotoxic T-lymphocyte-associated 
(CTLA)-4 monoclonal antibody (IgG1κ) [5]. The recommended dose for the 
treatment of advanced renal cell carcinoma (RCC) is 3 mg/kg of nivolumab 
administered IV over 30 minutes followed by 1 mg/kg of ipilimumab admin-
istered IV over 30 minutes on the same day, every 3 weeks for a maximum of 
4 doses, then 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks, 
administered IV over 30 minutes [6]. Ipilimumab can cause severe and fatal 
immune-mediated adverse reactions; most commonly including enterocol-
itis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy 
and endocrinopathy. If a severe immune-mediated adverse reaction occurs, 
ipilimumab must be discontinued permanently and a systemic high-dose 
corticosteroid therapy must be administered. Patients must be assessed for 
signs and symptoms of enterocolitis, dermatitis, neuropathy, and endocrino-
nivolumab is an Ig4 
antibody directed 
against PD-1 
combination regimen: 
nivolumab  
3 mg/kg IV + ipilimumab  
1 mg/kg IV every 3 
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nivolumab as single 
agent for maintenance 
therapy 
corticosteroids and 
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to treatment 
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warning of severe and 
fatal immune-mediated 
adverse reactions 
Nivolumab (Opdivo
®
) in combination with ipilimumab (Yervoy
®
) for the 
first-line treatment of patients with advanced RCC 
LBI-HTA | 2018 9 
pathy. At baseline and before each dose of ipilimumab, an evaluation of clin-
ical chemistries including liver function tests, adrenocorticotropic hormone 
(ACTH) level and thyroid function tests should be conducted [6]. With ref-
erence to combination therapy, immune-related adverse reactions occurred 
more often when nivolumab was administered in combination with ipili-
mumab compared to nivolumab monotherapy [5]. 
Sunitinib (Sutent
®
) is an inhibitor of multiple receptor tyrosine kinases 
(RTKs); it is indicated for the treatment of advanced/metastatic renal cell 
carcinoma (RCC) in adult patients. The recommended dose of sunitinib for 
the treatment of metastatic RCC is 50 mg per day for four consecutive 
weeks, followed by a two-week rest period, adding up to a complete cycle of 
six weeks. Sunitinib is available as hard capsules for oral administration. 
The most serious adverse reactions (some of them fatal) associated with the 
administration of sunitinib are renal or heart failure, pulmonary embolism, 
gastrointestinal perforation and haemorrhages; the most common adverse 
reactions of any grade are decreased appetite, taste disturbance, hyperten-
sion, fatigue, gastrointestinal disorders, skin discolouration and palmar-
plantar erythrodysesthesia syndrome. Furthermore, hypothyroidism or 
haematological disorders may develop during sunitinib treatment. Fatal 
events that were considered to be possibly related to the administration of 
sunitinib included multisystem organ failure, disseminated intravascular 
coagulation, peritoneal haemorrhage, adrenal insufficiency, pneumothorax, 
shock and sudden death [7]. 
 
A0022: Who manufactures nivolumab? 
Bristol-Myers Squibb 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Nivolumab (Opdivo
®
) in combination with ipilimumab (Yervoy
®
) is indi-
cated in patients with previously untreated advanced RCC with a clear-cell 
component. 
 
 
 
 
 
sunitinib: oral inhibitor 
of multiple RTKs  
first-line therapy for 
patients with advanced 
RCC 
Horizon Scanning in Oncology 
10 LBI-HTA | 2018 
4 Current regulatory status 
A0020: For which indications has nivolumab received marketing authorisa-
tion? 
In June 2015, the European Medicines Agency (EMA) initially granted mar-
keting authorisation for nivolumab (Opdivo
®
) for the treatment of advanced 
(unresectable or metastatic) melanoma in adults. To date, nivolumab has not 
been approved for the treatment of patients with untreated advanced RCC. 
Nivolumab has been approved by the EMA for the following indications [8]: 
 As monotherapy for the treatment of advanced RCC after prior 
therapy in adults. 
 As monotherapy or in combination with ipilimumab for the treat-
ment of advanced (unresectable or metastatic) melanoma in adults. 
Relative to nivolumab monotherapy, an increase in progression-free 
survival (PFS) for the combination of nivolumab with ipilimumab 
has been established only in patients with low tumour PD-L1 ex-
pression. According to Opdivo
® 
label information [2], before initiat-
ing treatment with the combination, physicians are advised to care-
fully evaluate the individual patient and tumour characteristics, 
taking into consideration the observed benefits and the toxicity of 
the combination relative to nivolumab monotherapy. 
 As monotherapy for the treatment of locally advanced or metastatic 
non-small cell lung cancer (NSCLC) after prior chemotherapy in 
adults. 
 As monotherapy for the treatment of adult patients with relapsed or 
refractory classical Hodgkin lymphoma after autologous stem cell 
transplant (ASCT) and treatment with brentuximab vedotin. 
 As monotherapy for the treatment of squamous cell cancer of the 
head and neck in adults progressing on or after platinum-based 
therapy. 
 For the treatment of locally advanced unresectable or metastatic 
urothelial carcinoma in adults after failure of prior platinum-
containing therapy. 
In April 2018, the FDA approved nivolumab in combination with ipili-
mumab for the treatment of patients with intermediate- or poor-risk ad-
vanced RCC who had not received prior therapy. In the US, nivolumab is al-
so approved for the following indications [9]: 
 In patients with advanced RCC who have received prior anti-
angiogenic therapy. 
 As a single agent for the treatment of patients with BRAF V600 
wild-type unresectable or metastatic melanoma and in patients with 
BRAF V600 mutation-positive unresectable or metastatic melano-
ma (accelerated approval based on PFS). 
 In patients with unresectable or metastatic melanoma, in combina-
tion with ipilimumab (accelerated approval based on PFS). 
currently not approved 
for untreated RCC by 
the EMA 
approved indications in 
Europe 
04/2018: FDA approval 
of nivolumab + 
ipilimumab for 
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 In patients with melanoma with lymph node involvement or meta-
static disease who have undergone complete resection, in the adju-
vant setting. 
 For the treatment of patients with metastatic NSCLC and progres-
sion on or after platinum-based chemotherapy. Patients with epi-
dermal growth factor receptor (EGFR) or anaplastic lymphoma ki-
nase (ALK) genomic tumour aberrations should have disease pro-
gression on FDA-approved therapy for these aberrations prior to 
receiving nivolumab. 
 In adult patients with classical Hodgkin lymphoma that has re-
lapsed or progressed after autologous haematopoietic stem cell 
transplantation (HSCT) and brentuximab vedotin, or three or more 
lines of systemic therapy that includes autologous HSCT. Both in-
dications are approved under accelerated approval based on overall 
response rate (ORR) and duration of response (DOR). 
 For the treatment of patients with recurrent or metastatic squa-
mous cell carcinoma of the head and neck with disease progression 
on or after platinum-based therapy. 
 In patients with locally advanced or metastatic urothelial carcino-
ma who have disease progression during or following platinum-
containing chemotherapy or who have disease progression within 
twelve months of neoadjuvant or adjuvant treatment with plati-
num-containing chemotherapy. Both indications are approved un-
der accelerated approval based on ORR and DOR data. 
 In adult and paediatric (twelve years and older) patients with mi-
crosatellite instability-high (MSI-H) or mismatch repair deficient 
(dMMR) metastatic colorectal cancer that has progressed following 
treatment with fluoropyrimidine, oxaliplatin and irinotecan (under 
accelerated approval based on ORR and DOR data). 
 For the treatment of patients with hepatocellular carcinoma (HCC) 
who have been previously treated with sorafenib (under accelerated 
approval based on ORR and DOR data). 
 
 
 
5 Burden of disease 
A0002: What is renal cell carcinoma? 
80% to 85% of all primary renal neoplasms are RCCs that originate within the 
renal cortex. Histologically, the majority of RCCs have a clear-cell component 
(75–85% of tumours); less common subtypes of RCCs are papillary carcino-
mas, chromophobe carcinomas, oncocytomas, collecting duct (Bellini’s duct) 
tumours and translocation carcinomas. Clear-cell carcinomas arise from the 
proximal tubule and are macroscopically solid or – less common – cystic. Typ-
ically, RCCs with a clear-cell component have a deletion of chromosome 3p 
[10]. 
 
RCCs arise from the 
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histologically, clear-cell 
pattern is most common 
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A0004: What is the natural course of renal cell carcinoma? 
Many patients with RCC are asymptomatic until the disease is either locally 
advanced and unresectable, or metastatic. Although surgical resection can be 
curative in patients with localised disease, many patients who are resectable 
may eventually recur. Generally, the prognosis for long-term disease-free 
survival is poor, the same accounts for patients with locally advanced or 
metastatic disease [11]. 
In Austria, the relative survival rate following diagnosis in patients with 
RCC (2008–2012) is 84.9% at one year, 79.2% at three years and 76.2% at 
five years. The age-standardised mortality rate for the European Standard 
Population for RCC (2015) is 7.3 per 100,000 per year in men and 3.4 per 
100,000 per year in women [12]. 
 
A0006: What are the consequences of renal cell carcinoma for the society? 
A0023: How many people belong to the target population? 
The median age of diagnosis of RCC is 67 years in men and 72 years in 
women [13]. According to data from the US (2011–2015), the median age at 
diagnosis of kidney and renal pelvis cancer is 64 years [14]. 
In Austria, 1,258 persons per year (2015) are newly diagnosed with RCC 
which is more frequent in men than in women, with 813 newly diagnosed 
men compared to 445 newly diagnosed women per year (2015). The age-
standardised incidence rate for the European Standard Population for RCC 
(2015) is 21.1 per 100,000 per year in men and 9.6 per 100,000 per year in 
women [12]. Since approximately 25% of patients have distant metastases or 
advanced locoregional disease at the time of presentation [11], the target 
population in Austria includes approximately 315 persons per year. 
 
A0005: What are the symptoms and the burden of renal cell carcinoma? 
Patients with RCC can present with a range of symptoms. However, many 
patients are asymptomatic until the disease is at an advanced stage and more 
than 50% of RCC cases are detected incidentally [15]. The classical triad 
symptoms of flank pain, haematuria and palpable abdominal renal mass – 
strongly suggesting locally advanced disease – are thus found less frequently. 
Symptoms that may result from metastatic disease include: haematuria, 
which occurs when the tumour affects the collecting system, involvement of 
the vena cava that can lead to lower extremity oedema, ascites, hepatic dys-
function and pulmonary emboli. Scrotal varicoceles (mostly left-sided) can 
be found in as many as 11% of men affected by RCC. In patients with dis-
seminated disease the most common involved sites include the lungs, lymph 
nodes, bones, liver and brain; symptoms include bone pain, adenopathy and 
pulmonary symptoms. Possible paraneoplastic symptoms are anaemia, he-
patic dysfunction, fever (in up to 20% of patients), hypercalcaemia (in up to 
15% of patients with advanced disease), cachexia, erythrocytosis, secondary 
amyloidosis, thrombocytosis, and polymyalgia rheumatica. The occurrence 
of RCC in patients that are ≤46 years may indicate an inheritable disease 
that should be further evaluated [11, 15, 16]. 
 
 
often diagnosed at an 
advanced stage 
RCC: 5-year relative 
survival rate is 76.2% 
Austria: 1,258/year 
newly diagnosed with 
RCC 
  
median age at diagnosis 
of RCC: 64 years 
often asymptomatic 
until advanced disease 
stage 
 
>50% of RCC cases are 
detected incidentally 
 
classical triad: flank 
pain, flank mass, 
haematuria 
 
 
paraneoplastic 
symptoms 
Nivolumab (Opdivo
®
) in combination with ipilimumab (Yervoy
®
) for the 
first-line treatment of patients with advanced RCC 
LBI-HTA | 2018 13 
A0003: What are the known risk factors for renal cell carcinoma? 
There are several established risk factors for the development of RCCs, in-
cluding cigarette smoking and hypertension. Another risk factor is obesity, 
since the relative risk of RCC increases progressively with the baseline body 
mass index (BMI). Additionally, the following factors that lead to chronic 
renal failure can increase the risk of developing RCC: an acquired cystic 
disease of the kidney (in approximately 35–50% of chronic dialysis patients 
from whom approximately 6% eventually develop RCC), an occupational 
exposure to toxic compounds (e.g. cadmium, asbestos, petroleum by-
products) and the prolonged ingestion of analgesic combinations. Patients 
who have been initially treated for renal cancer have an increased risk of de-
veloping a second, metachronous RCC. Moreover, the use of cytotoxic 
chemotherapy in childhood has been associated with the subsequent devel-
opment of translocation carcinomas. Further established risk factors for 
RCC are a chronic hepatitis C infection, sickle cell disease (risk of renal 
medullary carcinoma) and a history of kidney stones [10]. Approximately 2–
3% of all RCCs are hereditary and associated with several autosomal domi-
nant syndromes [15]; clear-cell carcinomas are specifically associated with 
von-Hippel-Lindau disease [10]. 
 
A0024: How is renal cell carcinoma currently diagnosed according to pub-
lished guidelines and in practice? 
When RCC is suspected, an initial physical examination and evaluation of 
the patient’s medical history should be performed. Laboratory examinations 
including serum creatinine, haemoglobin, leukocyte and platelet counts, 
lymphocyte-to-neutrophil ratio, lactate dehydrogenase, C-reactive protein 
(CRP) and serum-corrected calcium, as well as other symptom-derived tests 
are necessary. Patients affected by RCC typically present with a suspicious 
mass involving the kidney which is usually detected by a radiographic study. 
A computed tomography (CT) enables assessment of local invasiveness, in-
volvement of lymph nodes or the presence of distant metastases. Additional 
information regarding local advancement and venous involvement can be 
yielded by the use of magnetic resonance imaging (MRT). Contrast-
enhanced chest, abdominal and pelvic CT is mandatory for the staging of 
RCC. For routine clinical practice, the use of a bone scan or CT/MRT of the 
brain is not recommended, unless it is indicated by clinical or laboratory 
signs or symptoms. The European Society for Medical Oncology (ESMO) 
recommends a renal core biopsy to confirm malignancy before treatment 
with ablative therapies and in patients with metastatic disease prior to start-
ing systemic treatment. Finally, histopathological diagnosis, classification, 
grading and evaluation of prognostic factors can be based on the specimen 
obtained by nephrectomy [15, 16]. 
To determine the prognosis of patients with metastatic disease, the Interna-
tional Metastatic Renal Cell Carcinoma Database Consortium (IMDC) 
model is used to classify the patient’s risk as favourable, intermediate or un-
favourable/poor. The prognostic model comprises six factors: Karnofsky per-
formance status (PS) <80%, haemoglobin under the lower limit of normal, 
time from diagnosis to treatment of <1 year, corrected calcium above the 
upper limit of normal (ULN), platelets greater than the ULN, and neutro-
phils greater than the ULN [15]. 
 
established risk factors: 
smoking, hypertension 
and obesity 
 
 
 
 
 
 
 
2–3% of RCCs are 
hereditary 
physical examination, 
medical history 
evaluation, laboratory 
examinations 
 
 
 
CT, optional MRT 
 
 
 
 
 
 
specimen can be 
obtained by 
nephrectomy 
IMDC: favourable, 
intermediate or 
unfavourable/poor risk 
Horizon Scanning in Oncology 
14 LBI-HTA | 2018 
 
 
6 Current treatment 
A0025: How is renal cell carcinoma currently managed according to pub-
lished guidelines and in practice? 
According to ESMO [15], the following options for the treatment of meta-
static RCC are recommended:  
 Regarding local therapy and surgery, cytoreductive nephrectomy is 
only recommended in patients having a good PS and large primary 
tumours with limited volume of metastatic disease as well as in pa-
tients with a symptomatic primary lesion. 
 For selected patients, metastasectomy and other local treatment 
strategies (e.g. whole-brain radiotherapy, conventional radiothera-
py, stereotactic radiosurgery, stereotactic body radiotherapy, cyber-
knife radiotherapy, and hypofractionated radiotherapy) can be con-
sidered after multidisciplinary review. 
For systemic treatment in patients with good or intermediate risk, ESMO 
recommends: 
 First-line:  
- sunitinib 
- bevacizumab + interferon 
- pazopanib 
- optional: high-dose interleukin-2, sorafenib, bevaci-
zumab + low-dose interferon 
 Second-line (post cytokines):  
- axitinib 
- sorafenib 
- pazopanib 
- optional: sunitinib 
 Third-line treatment after two tyrosine kinase inhibitors 
(TKIs): 
- nivolumab 
- cabozantinib 
- optional: everolimus 
 Third-line treatment after TKI and mammalian target of 
rapamycin (mTOR): 
- sorafenib 
- nivolumab 
- cabozantinib 
- optional: other TKI or rechallenge. 
For systemic treatment of patients with poor risk, recommended therapy op-
tions are: 
 First-line treatment: 
- temsirolimus 
- optional: sunitinib, sorafenib, pazopanib 
 Second-line treatment (post-TKIs): 
ESMO treatment 
recommendations for 
metastatic RCC  
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- nivolumab 
- cabozantinib  
- optional: axitinib, everolimus, sorafenib 
 Third-line treatment (after TKI/nivolumab): 
- cabozantinib 
- optional: axitinib, everolimus 
 Third-line treatment (after TKI/cabozantinib): 
- nivolumab 
- optional: everolimus, axitinib [15]. 
According to their updated guidelines [17], the European Association of 
Urology (EAU) strongly recommends to offer ipilimumab plus nivolumab 
for treatment-naïve patients with IMDC intermediate- and poor-risk meta-
static clear-cell RCC. However, according to the EMA, nivolumab is indicat-
ed as monotherapy for the treatment of advanced RCC after prior therapy in 
adults and the assessed treatment option has not yet been approved. 
 
 
 
7 Evidence 
A literature search was conducted on 13 June 2018 in four databases: CRD 
Database, Embase, Ovid Medline and PubMed. Search terms were 
“nivolumab”, “opdivo”, “ipilimumab”, “mdx1106”, “renal cell carcinoma”, 
“kidney cancer” and “advanced”. Also, the manufacturer was contacted, who 
submitted four references (three of them had already been identified by sys-
tematic literature search) as well as additional safety data. A manual search 
identified 28 additional references (web documents and journal articles). 
Overall, 224 references were identified. Included in this reported are:  
 a randomised, open-label phase III trial, comparing nivolumab plus 
ipilimumab versus sunitinib monotherapy in untreated patients 
with advanced renal cell carcinoma [18]. 
 an open-label, parallel-cohort, dose-escalation phase I study to 
evaluate the efficacy and safety of nivolumab plus ipilimumab or 
nivolumab and a TKI in patients with mRCC [19]. 
To assess the risk of bias at the study level, assessment of the methodological 
quality of the evidence was conducted based on the EUnetHTA internal va-
lidity of randomised controlled trials (RCTs) [20]. Evidence was assessed 
based on the adequate generation of the randomisation sequence, allocation 
concealment, blinding of patients and treating physicians, selective outcome 
reporting and other aspects that may increase the risk of bias. Study quality 
details are reported in Table 6 (see appendix). 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effective-
ness assessment of pharmaceuticals, considering the following elements: 
population, intervention, comparator, outcomes and setting (see Table 5) 
[21]. 
EAU recommendation 
systematic literature 
search in 4 databases:  
196 hits 
 
 
manual search: 28 
additional references 
 
overall: 224 references 
included: 2 studies 
study-level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of study 
results 
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To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [22]. Additionally, an adapted version (due to perceived 
limitations) of ESMO-MCBS was applied [23]. Details of the magnitude of 
the clinically meaningful benefit scale are reported in Table 3. 
 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
 
7.2. Clinical efficacy and safety –  
phase III study 
CheckMate 214 [18, 24, 25] is a randomised, open-label phase III trial evalu-
ating the efficacy and safety of nivolumab plus ipilimumab versus sunitinib. 
For that reason, a total of 1,096 patients were randomly assigned between 
October 2014 and February 2016 at 175 sites in 28 countries throughout 
Asia, Europe, Australia and America. Included patients had to have previ-
ously untreated advanced RCC with a clear-cell component. According to 
IMDC, 425 patients treated with nivolumab plus ipilimumab and 422 pa-
tients treated with sunitinib had intermediate- or poor-risk RCC (79% of the 
overall study population), respectively. IMDC intermediate- and poor-risk 
patients had a median age of 62 years in the nivolumab-plus-ipilimumab 
group and 61 years in the sunitinib group. 26% of patients in the nivolumab-
plus-ipilimumab group and 29% of patients in the sunitinib group were fe-
magnitude of 
meaningful clinical 
benefit assessed based 
on ESMO-MCBS 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
CheckMate 214: 
randomised, open-label 
phase III trial 
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male. 79% (nivolumab-plus-ipilimumab group) and 80% (sunitinib group) 
of patients with IMDC intermediate or poor risk had two or more sites with 
target or non-target lesions. 80% of patients of the nivolumab-plus-
ipilimumab group and 76% of patients of the sunitinib group had previously 
undergone nephrectomy, 12% of patients of both groups had previously re-
ceived radiotherapy. 74% of patients receiving nivolumab plus ipilimumab 
and 71% of sunitinib group patients showed less than 1% of quantifiable 
tumour PD-L1 expression. The most common sites of metastasis among pa-
tients of both groups were the lung and lymph nodes. Baseline demographic 
and clinical characteristics were similar in patients of the intention-to-treat 
(ITT) population that included patients with favourable, intermediate or 
poor risk. Detailed patient characteristics including inclusion and exclusion 
criteria can be found in Table 5. 
Patients received nivolumab IV at a dose of 3 mg/kg over a period of 60 
minutes and ipilimumab at a dose of 1 mg/kg over a period of 30 minutes, 
both every three weeks for four doses during the induction phase. In the 
subsequent maintenance phase, nivolumab monotherapy was administered 
at a dose of 3 mg/kg every two weeks. Patients of the sunitinib group re-
ceived their study drug at a dose of 50 mg orally once daily for four weeks of 
each six-week cycle.  
The co-primary endpoints of the CheckMate 214 trial were ORR, PFS and 
overall survival (OS) among intermediate- or poor-risk patients. Secondary 
endpoints were ORR, PFS and OS in the ITT population as well as the inci-
dence rate of adverse events (AEs) among all treated patients. Exploratory 
endpoints were ORR, PFS and OS in patients with IMDC favourable risk. 
Additional exploratory endpoints were health-related quality of life 
(HRQoL) and outcomes according to the level of tumour PD-L1 expression. 
Database lock was on 7 August 2017; at that time, 23% in the nivolumab-
plus-ipilimumab group and 18% of patients in the sunitinib group contin-
ued treatment. In patients who discontinued treatment, the most common 
reason for discontinuation was disease progression with 42% of patients in 
the nivolumab-plus-ipilimumab group and 55% of patients in the sunitinib 
group. Less common reasons were study drug toxicities and AEs unrelated 
to the study drug.  
The median follow-up in the CheckMate 214 trial was 25.2 months, with a 
minimum follow-up of 17.5 months. The median duration of treatment in 
patients receiving nivolumab plus ipilimumab was 7.9 months (95% confi-
dence interval, CI, 6.5–8.4) and 7.8 months (95% CI, 6.4–8.5) in patients of 
the sunitinib group. 79% of patients received all four doses of nivolumab 
plus ipilimumab. 39% of patients in the nivolumab-plus-ipilimumab group 
received subsequent systemic therapy, most commonly with sunitinib and 
pazopanib. Among sunitinib group patients, 54% received subsequent sys-
temic therapy, with nivolumab and axitinib being administered most fre-
quently. 
According to a protocol amendment in November 2017, patients were per-
mitted to cross over from the sunitinib group to the nivolumab-plus-
ipilimumab group after the primary endpoint had been met. It is worthy of 
note that the CheckMate 214 trial is currently ongoing, with an estimated 
study completion date of September 2019. 
 
nivolumab  
3 mg/kg + ipilimumab  
1 mg/kg every  
3 weeks for 4 doses, 
then nivolumab  
3 mg/kg every  
2 weeks 
 
sunitinib: 50 mg once 
daily for  
4 weeks 
co-primary endpoints: 
ORR, PFS, OS among 
intermediate- and poor-
risk patients 
treatment 
discontinuation in 42% 
(nivolumab-plus-
ipilimumab group) and 
55% (sunitinib group) 
median duration of 
treatment: 7.9 months 
(nivolumab + 
ipilimumab) vs. 7.8 
months (sunitinib 
group) 
 
permission to cross over 
after primary endpoint 
was met 
 
CheckMate 214: ongoing 
until 09/2019 
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7.2.1  Clinical efficacy 
D0001: What is the expected beneficial effect of nivolumab on mortality? 
OS in intermediate- and poor-risk patients (n = 847) was a co-primary end-
point in the CheckMate 214 trial. Efficacy analyses showed a statistically 
significant OS benefit in patients receiving nivolumab plus ipilimumab over 
patients who received sunitinib. The 12-month OS rate was 80% (95% CI, 
76–84) in patients of the nivolumab-plus-ipilimumab group versus 72% 
(95% CI, 67–76) in patients of the sunitinib group. 18-month OS rates were 
75% (95% CI, 70–78) in patients receiving nivolumab plus ipilimumab ver-
sus 60% (95% CI, 55–65) in sunitinib group patients with a hazard ratio 
(HR) for death of 0.63 (99.8% CI, 0.44–0.89; p <0.001). Median OS was not 
reached (95% CI, 28.2 months–NE1) in patients of the nivolumab-plus-
ipilimumab group and was 26.0 months (95% CI, 22.1–NE) in patients re-
ceiving sunitinib. The OS benefit of nivolumab plus ipilimumab was shown 
across all subgroups; even if its extent differed among the subgroups. 
OS in the ITT population (n = 1096) was a secondary endpoint; the 12-
month OS rate and the 18-month OS rate were 83% (95% CI, 80–86) and 
78% (95% CI, 74–81) in patients of the nivolumab-plus-ipilimumab group 
versus 77% (95% CI, 74–81) and 68% (95% CI, 63–72) in patients of the 
sunitinib group, respectively. Median OS was not reached in patients who 
received nivolumab plus ipilimumab and was 32.9 months in patients who 
received sunitinib. The OS benefit was statistically significantly higher in 
the nivolumab-plus-ipilimumab group compared to the sunitinib group: HR 
for death was 0.68 (99.8% CI, 0.49–0.95; p <0.001). 
The 12-month OS rate and the 18-month OS rate of favourable-risk patients 
(n = 249) was 94% (95% CI, 87–97) and 88% (95% CI, 80–92) in patients 
treated with nivolumab plus ipilimumab versus 96% (95% CI, 90–98) and 
93% (95% CI, 87–97) in patients receiving sunitinib, respectively. With 1.45 
(99.8% CI, 0.51–4.12; p = 0.27), HR for death favoured sunitinib treatment. 
Median OS was not reached in patients of the nivolumab-plus-ipilimumab 
group and was 32.9 months (95% CI, NE) in the sunitinib group. At the time 
of database lock (August 7, 2017), 37 deaths had occurred in this subpopula-
tion. 
Exploratory analyses showed that among the 776 intermediate- and poor-
risk patients who had quantifiable PD-L1 expression, OS was longer across 
PD-L1 expression levels in patients receiving nivolumab plus ipilimumab 
than in patients receiving sunitinib. In patients with PD-L1 expression less 
than 1%, the 12-month and the 18-month OS rates were 80% (95% CI, 75–
84) and 74% (95% CI, 69–79) in patients of the nivolumab-plus-ipilimumab 
group versus 75% (95% CI, 70–80) and 64% (95% CI, 58–70) in patients of 
the sunitinib group. In both groups, median OS was not reached; HR for 
death was 0.73 (95% CI, 0.56–0.96).  
In patients with PD-L1 expression of 1% or greater (n = 214), the 12-month 
and the 18-month OS rates were 86% (95% CI, 77–91) and 81% (95% CI, 71–
87) in patients receiving nivolumab plus ipilimumab compared to 66% (95% 
CI, 56–74) and 53% (95% CI, 43–62) in patients receiving sunitinib. Median 
OS was not reached in the nivolumab-plus-ipilimumab group and was 19.6 
                                                             
1
 NE = not estimable 
nivolumab + 
ipilimumab: statistically 
significant OS benefit in 
intermediate- and poor-
risk patients 
nivolumab + 
ipilimumab: statistically 
significant OS benefit in 
the ITT population 
favourable-risk patients: 
better results when 
treated with sunitinib 
exploratory analyses: 
prolonged OS in 
intermediate- and poor-
risk patients who had 
quantifiable PD-L1 
expression 
PD-L1 expression  
≥1%: higher OS rates 
with nivolumab-plus-
ipilimumab 
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months (95% CI, 14.8–NE) in the sunitinib group, resulting in a HR for 
death of 0.45 (95% CI, 0.29–0.71).  
 
D0006: How does nivolumab affect progression (or recurrence) of renal cell 
carcinoma? 
PFS in intermediate- and poor-risk patients (n = 847) was a co-primary 
endpoint in the CheckMate 214 trial; median PFS was 11.6 months (95% CI, 
8.7–15.5) in patients of the nivolumab-plus-ipilimumab group versus 8.4 
months (95% CI, 7.0–10.8) in sunitinib group patients. However, the be-
tween-group difference (HR for disease progression or death of 0.82, 99.1% 
CI, 0.64–1.05, p = 0.03) did not meet the pre-specified threshold of p = 
0.009 and thereby fails to be of statistical significance. 
Among patients of the ITT population (n = 1096), PFS did not differ statis-
tically significantly either between patients receiving nivolumab plus ipili-
mumab and patients receiving sunitinib (HR for disease progression or 
death of 0.98, 99.1% CI, 0.79–1.23; p = 0.85). Median PFS was 12.4 months 
(95% CI, 9.9–16.5) in patients of the nivolumab-plus-ipilimumab group and 
12.3 months (95% CI, 9.8–15.2) in patients of the sunitinib group. 
In patients with IMDC favourable risk (n = 249), median PFS was 15.3 
months (95% CI, 9.7–20.3) in the nivolumab-plus-ipilimumab group and 
25.1 months (95% CI, 20.9–NE) with a HR of 2.18 (99.1% CI, 1.29–3.68; p 
<0.001), in favour of the sunitinib group. 
Patients with a PD-L1 expression level of lower than 1% (n = 562) had a 
median PFS of 11.0 months (nivolumab-plus-ipilimumab group) versus 10.4 
months (sunitinib group), resulting in a HR for disease progression or death 
of 1.00 (95% CI, 0.80–1.26). Patients showing a PD-L1 expression of 1% or 
greater (n = 214) had a median PFS of 22.8 months in patients receiving 
nivolumab plus ipilimumab and 5.9 months in patients receiving sunitinib 
(HR for disease progression or death of 0.46, 95% CI, 0.31–0.67). 
 
D0005: How does nivolumab affect symptoms and findings (severity, fre-
quency) of renal cell carcinoma? 
ORR was another co-primary endpoint of the CheckMate 214 trial. In the in-
termediate- and poor-risk subpopulation (n = 847) analyses have shown an 
ORR of 42% (95% CI, 37–47) in patients receiving nivolumab plus ipili-
mumab versus 27% (95% CI, 22–31) in patients receiving sunitinib (p 
<0.001). Of all intermediate- and poor-risk patients who received nivolumab 
plus ipilimumab, 9%, 32%, 31% and 20% achieved complete response (CR), 
partial response (PR), stable disease and progressive disease, respectively. 
Intermediate- and poor-risk patients of the sunitinib group achieved CR, 
PR, stable disease and progressive disease in 1%, 25%, 45% and 17%, re-
spectively. The median time to response was 2.8 months (ranging from 0.9 to 
11.3 months) in patients of the nivolumab-plus-ipilimumab group and 3.0 
months (ranging from 0.6 to 15.0 months) in patients of the sunitinib group. 
81% of all patients with intermediate- or poor-risk RCC who received 
nivolumab plus ipilimumab and 70% of patients who were treated with 
sunitinib showed a duration of response of at least one year. Overall, the 
median duration of response was not reached among patients of the 
nivolumab-plus-ipilimumab group (95% CI, 21.8 months–NE); patients of 
the sunitinib group had a median duration of response of 18.2 months (95% 
intermediate-/poor-risk 
patients: PFS with 
nivolumab + ipilimumab 
improved, but not 
statistically significantly 
ITT population: no 
statistically significant 
difference 
favourable-risk patients: 
PFS in favour of 
sunitinib 
PD-L1 expression  
<1%:  
+0.6 months median 
PFS 
 
PD-L1 expression  
≥1%:  
+16.9 months median 
PFS 
intermediate- or poor-
risk patients: ORR 42% 
with nivolumab + 
ipilimumab vs. 27% with 
sunitinib 
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CI, 14.8 months–NE). Data from the first interim analyses showed that 72% 
of patients treated with nivolumab plus ipilimumab and 63% of patients 
who received sunitinib had an ongoing response.  
Among patients of the ITT population (n = 1096), ORR was 39% (95% CI, 
35–43) in patients of the nivolumab-plus-ipilimumab group and 32% (95% 
CI, 28–36) in patients who received sunitinib, resulting in p = 0.02, which is 
not statistically significant regarding the pre-specified threshold of p = 
0.001. 
Among favourable-risk patients (n = 249), ORR was 29% (95% CI, 21–38) in 
patients treated with nivolumab plus ipilimumab compared to 52% (95%CI 
43–61) in patients who were treated with sunitinib (p <0.001). The rate of 
CR was 11% in patients of the nivolumab-plus-ipilimumab group and 6% in 
patients of the sunitinib group. 
In patients with a PD-L1 expression lower than 1% (n = 562), ORR was 
37% in patients of the nivolumab-plus-ipilimumab group versus 28% in pa-
tients of the sunitinib group (p = 0.03). Patients showing a PD-L1 expres-
sion of 1% or greater (n = 214) had an ORR of 58% (nivolumab-plus-
ipilimumab group) versus 22% (sunitinib group), resulting in a statistically 
significant difference (p <0.001). 
 
D0011: What is the effect of nivolumab on patients’ body functions? 
Based on analyses of the National Comprehensive Cancer Net-
work/Functional Assessment of Cancer Therapy-Kidney Symptom Index 
(FKSI-19), patients who received nivolumab plus ipilimumab reported bet-
ter HRQoL than patients treated with sunitinib. Items of FKSI-19 include 
pain, fatigue, pulmonary symptoms, bowel/bladder symptoms, nutritional 
health, psychosocial functioning and treatment side effects. Detailed infor-
mation regarding HRQoL of patients participating in the CheckMate 214 
trial is presented below.  
 
D0012: What is the effect of nivolumab on generic health-related quality of 
life? 
HRQoL was assessed by using FKSI-19; the rate of completion of the FKSI-
19 questionnaire was higher than 80% in patients of either group during the 
first six months. Analyses showed that, among intermediate- and poor-risk 
patients, the mean change from baseline at each assessment during the first 
six months was greater in patients who were treated with nivolumab plus 
ipilimumab than in patients treated with sunitinib (p <0.001). The descrip-
tive results are substantiated by both the pattern-mixture model (a flexible 
and transparent way to analyse incomplete longitudinal data where the miss-
ingness is non-ignorable [26]) and the mixed-model repeated measures (a 
specialised mixed-model procedure that analyses results from repeated 
measures designs in which the outcome (response) is continuous and meas-
ured at fixed time points [27]), indicating a significant difference in favour 
of patients treated with nivolumab plus ipilimumab [18]. 
The assessed benefits in HRQoL of nivolumab plus ipilimumab over 
sunitinib were observed early during the induction phase and were generally 
maintained throughout the treatment including the nivolumab maintenance 
phase. Also, the benefits were apparent overall and across most domains of 
ITT population: 
difference not 
statistically significant 
favourable-risk patients: 
statistically significant 
improvement in 
sunitinib patients 
 
improved ORR 
independent of  
PD-L1 expression 
better HRQoL reported 
by nivolumab-plus-
ipilimumab-group 
patients 
<80% in both groups 
completed FKSI-19 
 
 
mean change from 
baseline greater in 
patients treated with 
nivolumab + ipilimumab 
benefits observed 
throughout the 
treatment  
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disease-related symptoms of kidney cancer (FKSI-19), general cancer 
(HRQoL) and health status (EQ-5D-3L) [28]. 
 
D0013: What is the effect of nivolumab on disease-specific quality of life? 
No evidence was found to answer this research question. 
 
 
Table 1: Efficacy results of the CheckMate 214 trial [18, 24] 
Descriptive sta-
tistics and esti-
mate variability 
Treatment group 
Nivolumab +  
ipilimumab  
Sunitinib 
Number of patients 
   Intermediate- and poor-risk patients 
   ITT population 
   Favourable-risk patients 
   Patients with quantifiable PD-L1 expression1 
   PD-L1 expression ≥1% 
   PD-L1 expression <1% 
 
425 
550 
125 
384 
100 
284 
 
422 
546 
124 
392 
114 
278 
OS 
    Intermediate- and poor-risk patients 
       12-month OS rate, % (95% CI) 
       18-month OS rate, % (95% CI) 
       Median OS, months (95% CI) 
     ITT population 
       12-month OS rate, % (95% CI) 
       18-month OS rate, % (95% CI) 
       Median OS, months  
     Favourable-risk patients 
       12-month OS rate, % (95% CI) 
       18-month OS rate, % (95% CI) 
       Median OS, months (95% CI) 
    Patients with PD-L1 <1% 
       12-month OS rate, % (95% CI) 
       18-month OS rate, % (95% CI) 
       Median OS, months  
    Patients with PD-L1 ≥ 1% 
       12-month OS rate, % (95% CI) 
       18-month OS rate, % (95% CI) 
       Median OS, months (95% CI) 
 
 
80 (76–84) 
75 (70–78) 
NR (28.2–NE) 
 
83 (80–86) 
78 (74–81) 
NR 
 
94 (87–97) 
88 (80–92) 
NR 
 
80 (75–84) 
74 (69–79) 
NR 
 
86 (77–91) 
81 (71–87) 
NR 
 
 
72 (67–76) 
60 (55–65) 
26.0 (22.1–NE) 
 
77 (74–81) 
68 (63–72) 
32.9 
 
96 (90–98) 
93 (87–97) 
32.9 (NE) 
 
75 (70–80) 
64 (58–70) 
NR 
 
66 (56–74) 
53 (43–62) 
19.6 (14.8–NE) 
PFS 
Intermediate- and poor-risk patients 
   Median PFS, months (95% CI) 
PFS in ITT population 
   Median PFS, months (95% CI) 
Favourable-risk patients 
   Median PFS, months (95% CI) 
   PD-L1 <1%, median PFS, months 
   PD-L1 ≥1%, median PFS, months 
 
 
11.6 (8.7–15.5) 
 
12.4 (9.9–16.5) 
 
15.3 (9.7–20.3) 
11.0 
22.8 
 
 
8.4 (7.0–10.8) 
 
12.3 (9.8–15.2) 
 
25.1 (20.9–NE) 
10.4 
5.9 
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Abbreviations: CI = confidence interval, CR = complete response, HR = hazard ratio, HRQoL = health-related quality of life, 
ITT = intention to treat, NA = not available, NE = not estimable, NR = not reached, OR = overall response, ORR = 
objective response rate, OS = overall survival, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, PR = 
partial response 
1
among 776 intermediate- and poor-risk patients  
 
 
 ORR  
Intermediate- and poor-risk patients, % 
  Confirmed ORR, % (95% CI) 
  Confirmed best OR, % 
      CR 
      PR 
      Stable disease 
      Progressive disease 
      Unable to determine or not reported 
Median time to response, months (range) 
Median duration of response, months (95% CI) 
Patients with ongoing response, % 
ORR in ITT population, % (95% CI) 
ORR in favourable-risk patients, % (95% CI) 
ORR in patients with  
   PD-L1 <1%, % (95% CI) 
   PD-L1 ≥1%, % (95% CI) 
 
 
42 (37–47) 
 
9 
32 
31 
20 
8 
2.8 (0.9–11.3) 
NR (21.8–NE) 
72 
39 (35–43) 
29 (21–38) 
 
37 (32–43) 
58 (48–68) 
 
 
27 (22–31) 
 
1 
25 
45 
17 
12 
3.0 (0.6–15.0) 
18.2 (14.8–NE) 
63 
32 (28–36) 
52 (43–61) 
 
28 (23–34) 
22 (15–31) 
Effect estimate 
per comparison 
 
Comparison groups 
Nivolumab +  
ipilimumab 
versus sunitinib 
OS  
Intermediate- and poor-risk patients 
HR 0.63 
99.8% CI 0.44–0.89 
p-value <0.001 
ITT population HR 0.68 
99.8% CI 0.49–0.95 
p-value <0.001 
Favourable-risk patients HR 1.45 
99.8% CI 0.51–4.12 
p-value 0.27 
PD-L1 <1% HR 0.73 
95% CI 0.56–0.96 
p-value NA 
PD-L1 ≥1% HR 0.45 
95% CI 0.29–0.71 
p-value NA 
PFS 
Intermediate- and poor-risk patients 
HR 0.82 
99.1% 0.64–1.05 
p-value 0.03 
ITT population HR 0.98 
99.1% CI 0.79–1.23 
p-value 0.85 
Favourable-risk patients HR 2.18 
99.1% CI 1.29–3.68 
p-value <0.001 
PD-L1 <1% HR 1.00 
95% CI 0.80–1.26 
p-value NA 
 PD-L1 ≥1% HR 0.46 
95% CI 0.31–0.67 
p-value NA 
ORR 
Intermediate- and poor-risk patients 
 
p-value 
 
<0.001 
ITT patients p-value 0.02 
Favourable-risk patients p-value <0.001 
Patients with PD-L1 <1% p-value 0.03 
Patients with PD-L1 ≥1% p-value <0.001 
HRQoL p-value <0.001 
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7.2.2  Safety 
 
C0008: How safe is nivolumab in relation to the comparator? 
In 93% of nivolumab-plus-ipilimumab group patients and 97% of sunitinib 
group patients, treatment-related AEs of any grade occurred; grade 3 or 4 
treatment-related AEs were reported in 46% (nivolumab-plus-ipilimumab 
group) and 63% (sunitinib group) of patients.  
In patients of the nivolumab-plus-ipilimumab group, the most frequent 
treatment-related grade 3 or 4 AEs occurring in 15% or more of treated pa-
tients were an increased lipase level, fatigue and diarrhoea, while hyperten-
sion, fatigue and palmar-plantar erythrodysesthesia occurred most common-
ly in the sunitinib group. 22% of nivolumab-plus-ipilimumab group patients 
and 12% of sunitinib group patients discontinued study treatment due to 
treatment-related AEs. Among patients of the nivolumab-plus-ipilimumab 
group, eight treatment-related deaths were reported; one each due to pneu-
monitis, pneumonia and aplastic anaemia, immune-mediated bronchitis, 
lower gastrointestinal haemorrhage, haemophagocytic syndrome, sudden 
death, liver toxic effects and lung infection. In the sunitinib group, four 
treatment-related deaths occurred, two of them caused by cardiac arrest and 
one each due to heart failure and multiple organ failure.  
 
C0002: Are the harms related to dosage or frequency of applying nivolumab? 
There is evidence from clinical trials that nivolumab monotherapy or 
nivolumab in combination with ipilimumab caused severe infusion 
reactions. In such cases, the infusion must be discontinued and patients 
must receive an appropriate alternative medical therapy. Patients who 
experienced a mild or moderate infusion reaction may receive nivolumab 
monotherapy or nivolumab plus ipilimumab with close monitoring and the 
use of premedication to prevent the occurrence of infusion reactions [2]. 
Of 547 nivolumab-plus-ipilimumab group patients, 58% and 27% had 
nivolumab and ipilimumab dose delays, respectively. Among sunitinib 
group patients (n = 535), dose delays were reported from 59% of patients 
and 53% of patients had dose reductions. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of nivolumab? 
There is no data available regarding the safety and efficacy of nivolumab in 
children younger than 18 years. Although there is no data available on the 
use of nivolumab during pregnancy, its use is not recommended since 
nivolumab has the potential to be transmitted from the mother to the foetus. 
Women at childbearing age should use effective contraception. There is no 
data available on whether nivolumab is secreted in human milk; moreover, 
the effect of nivolumab on male or female fertility is not known. In patients 
with moderate or severe hepatic impairment, nivolumab has to be adminis-
tered with caution.  
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Table 2: CheckMate 214 trial: Treatment-related AEs occurring in ≥15% of treated patients in either group [18] 
 
Adverse event (according to 
NCI CTCAE version 4.0) 
 
Intervention (n = 547) Control (n = 535) 
 Any grade 
n (%) 
Grade 3 or 4 
n (%) 
Any grade 
n (%) 
Grade 3 or 4 
n (%) 
All events 509 (93) 250 (46) 521 (97) 335 (63) 
Fatigue 202 (37) 23 (4) 264 (49) 49 (9) 
Pruritus 154 (28) 3 (<1) 49 (9) 0 (0) 
Diarrhoea 145 (27) 21 (4) 278 (52) 28 (5) 
Rash 118 (22) 8 (1) 67 (13) 0 (0) 
Nausea 109 (20) 8 (1) 202 (38) 6 (1) 
Increased lipase level 90 (16) 56 (10) 58 (11) 35 (7) 
Hypothyroidism 85 (16) 2 (<1) 134 (25) 1 (<1) 
Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1) 
Asthenia 72 (13) 8 (1) 91 (17) 12 (2) 
Vomiting 59 (11) 4 (<1) 110 (21) 10 (2) 
Anaemia 34 (6) 2 (<1) 83 (16) 24 (4) 
Dysgeusia 31 (6) 0 (0) 179 (33) 1 (<1) 
Stomatitis 23 (4) 0 (0) 149 (28) 14 (3) 
Dyspepsia 15 (3) 0 (0) 96 (18) 0 (0) 
Mucosal inflammation 13 (2) 0 (0) 152 (28) 14 (3) 
Hypertension 12 (2) 4 (<1) 216 (40) 85 (16) 
Palmar-plantar 
erythrodysesthesia 
 
5 (<1) 
 
0 (0) 
 
231 (43) 
 
49 (9) 
Thrombocytopenia 2 (<1) 0 (0) 95 (18) 25 (5) 
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events, NCI = National Cancer Institute, n = number 
 
 
7.3 Clinical effectiveness and safety –  
further studies 
There are no further phase II or phase III trials available evaluating the 
combination regimen of nivolumab plus ipilimumab for the first-line treat-
ment of metastatic RCC. 
CheckMate 016 [19] is a phase I, open-label, multicentre, parallel-cohort, 
dose-escalation study assessing the efficacy and safety of nivolumab plus 
ipilimumab or nivolumab and a TKI in patients with mRCC. Patients who 
were eligible to receive nivolumab and ipilimumab were randomly assigned 
to receive either nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3I1, n = 
47), nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (N1I3, n = 47) or 
nivolumab 3 mg/kg plus ipilimumab 3 mg/kg (N3I3, n = 6). Eligible pa-
tients had histologically confirmed advanced RCC or mRCC with a clear-
cell component, measurable disease according to RECIST 1.1 and a 
Karnofsky performance status of at least 80% at study enrolment. Patients of 
the initial cohorts (designed to gain safety information) of the N3I1 and 
N1I3 groups could either have received no prior treatment or had received 
no further phase II/III 
trials for untreated 
mRCC available 
CheckMate 016: open-
label phase I study 
 
total of 5 treatment 
arms, patients of 3 arms 
received nivolumab + 
ipilimumab in different 
dosages 
 
endpoints: safety, 
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prior systemic therapy, whereas patients of the expansion cohorts (for safety 
and efficacy data) of the N3I1 , N1I3 and N3I3 groups were not allowed to 
have received prior systemic therapy for RCC.  
Patients of the N3I1 group had a median age of 53.0 years, and 91.5% of pa-
tients were male. According to the Memorial Sloan Kettering Cancer Center 
(MSKCC) risk classification, 44.7% of patients had favourable risk, 48.9% of 
patients had intermediate risk and 6.4% of patients had poor risk. 97.9%, 
31.9% and 46.8% of patients had prior surgery, prior radiotherapy and prior 
systemic therapy (most commonly with cytokines), respectively. More than 
half of patients (53.2%) did not receive any previous therapy; the most 
common treatment setting was metastatic (42.6%). The primary endpoint of 
the study was to evaluate overall safety and tolerability of the combination 
regimen nivolumab-plus-ipilimumab and to determine the maximum toler-
ated dose. Secondary endpoints were best overall response (BOR), ORR, 
DOR, time to response, PFS and 24-week PFS rate. Cut-off date of the 
CheckMate 016 trial was on 16 March 2016; the median follow-up was 22.3 
months, minimum follow-up was 22 months. Patients of the N3I1 arm re-
ceived a median of ten nivolumab doses, in patients of the N1I3 arm a medi-
an of seven nivolumab doses were administered.  
100% of patients of the N3I1 group and the N1I3 group experienced an AE 
of any grade. Among patients of the N3I1 arm, 91.5% of patients experi-
enced a treatment-related AE of any grade (most frequent were fatigue, rash 
and pruritus) and 38.3% of patients had a treatment-related AE of grade 3 or 
4. 95.7% of patients of the N1I3 arm had a treatment-related AE of any 
grade (most commonly fatigue, diarrhoea and pruritus) and 61.7% experi-
enced a grade 3 or 4 treatment-related AE. 100% and 83.3% of patients of 
the N3I3 group reported an AE of any grade (fatigue and hypothyroidism 
were most frequent) and grade 3 or 4, respectively. Serious AEs (SAEs) oc-
curred in 62.8% of patients of the N3I1 and N1I3 arms and 46.8% experi-
enced a grade 3 or 4 SAE. 28.7% and 26.6% of patients of these two groups 
reported a treatment-related SAE of any grade and a treatment-related SAE 
of grade 3 or 4, respectively. There were no grade 5 treatment-related SAEs 
in either treatment group. 
Due to the high censoring percentage, no efficacy results were presented for 
the N3I3 arm. In both the N3I1 and the N1I3 arm, the confirmed ORR was 
40.4%. 10.6% of patients of the N3I1 arm achieved a complete response and 
29.8% a partial response. In the N1I3 arm, no patient achieved a complete 
response, whereas 40.4% of patients had a partial response. In patients of the 
N3I1 arm, median OS was not reached; OS rate at 12 and 24 months was 
81% and 67%, respectively. Patients of the N1I3 arm had a median OS of 
32.6 months (95% CI, 26.0 months–not reached) and an OS rate at 12 and 24 
months of 85% and 70%, respectively.  
Among patients of the N3I1 group, median PFS was 7.7 months, PFS rates 
at 6, 12, 18 and 24 months were 55.6%, 40.0%, 28.9%, 18.7%. In the N1I3 
arm, median PFS was 9.4 months and PFS rates at 6, 12, 18 and 24 months 
were 63.8%, 46.4%, 37.6% and not calculated, respectively. 
 
 
 
N3I1  
(nivolumab  
3 mg/kg +  
ipilimumab  
1 mg/kg) patient 
characteristics  
high rates of AEs and 
SAEs, no treatment-
related deaths 
confirmed response in 
N3I1 and N1I3 arms: 
40.4% 
 
OS rate after 12 and 24 
months higher in N1I3 
arm 
median PFS: 7.7 months 
in N3I1 group and 9.4 in 
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8  Estimated costs 
A0021: What is the reimbursement status of nivolumab? 
Nivolumab (Opdivo
®
) is available as a concentrate for solution for infusion 
in vials of 4 mL (10 mg/mL) at € 572 and 10 mL (10 mg/mL) at € 1,430 (ex-
factory prices) [29].  
Patients of the CheckMate 214 trial received 3 mg/kg IV of nivolumab every 
three weeks for four doses (induction phase), followed by 3 mg/kg IV of 
nivolumab every two weeks in the maintenance phase. Median treatment 
duration in the CheckMate 214 trial was 7.9 months in patients of the 
nivolumab-plus-ipilimumab group [18].  
Assuming an average body weight of 70 kg, 210 mg of nivolumab is needed 
for one dose of nivolumab treatment, costing € 3,432, resulting in costs of € 
13,728 for the induction phase. Based on the median treatment duration of 
the CheckMate trial of 7.9 months comprising approximately 14 doses of 
nivolumab, treatment costs amount to € 48,048.  
Ipilimumab (Yervoy
®
) is available as a concentrate for solution for infusion 
in vials of 10 mL (5 mg/mL) at € 4,250 and 40 mL (5 mg/mL) at € 17,000 
(ex-factory prices) [29]. In patients of the CheckMate 214 trial, ipilimumab 
was administered at a dose of 1 mg/kg every three weeks for four doses. 
Based on an average body weight of 70 kg, 70 mg of ipilimumab is needed 
for one infusion resulting in costs of about € 34,000 for four doses. Based on 
these calculations, total costs for the induction phase would be € 47,728. In 
total, for 7.9 months of nivolumab-plus-ipilimumab combination therapy 
(comprising induction phase followed by maintenance phase), costs of ap-
proximately € 82,048 would incur.  
Sunitinib (Sutent
®
) is available as 12.5 mg, 25 mg or 50 mg hard capsule 
with 30 tablets at € 1,315, € 2,660 or € 5,260 (ex-factory prices), respectively 
[29]. Patients of the CheckMate 214 trial received 50 mg of sunitinib orally 
once daily for four weeks of each six-week cycle, resulting in costs of € 
5,260.0 for one cycle. Based on a median treatment duration of 7.8 months in 
CheckMate 214 trial patients, sunitinib treatment would cost approximately 
€ 26,300. 
 
 
 
9  Ongoing research 
In June 2018, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following phase III trials, 
assessing the administration of nivolumab in patients with RCC, were iden-
tified: 
 NCT02231749: CheckMate 214, the trial discussed in this as-
sessment, is ongoing. The estimated study completion date is 
September 2019. 
4 mL = € 572.0 
10 mL = € 1,430.0 
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4 doses of nivolumab =  
€ 13,728 
 
 
4 doses of ipilimumab =  
€ 34,000 
 
induction phase:   
€ 47,728 
 
maintenance phase: € 
6,864 per month 
sunitinib: € 5,260 for 
one six-week cycle 
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 NCT03138512: CheckMate 914 is a randomised trial comparing 
the combination of nivolumab and ipilimumab versus placebo 
in participants with localised RCC. The estimated study com-
pletion date is July 2023. 
 NCT03141177: CheckMate 9ER is a randomised, open-label 
study assessing the combination of nivolumab with cabozantin-
ib compared to sunitinib in previously untreated advanced or 
metastatic RCC. Estimated study completion date is April 2023. 
 NCT02940639 (study phase not available): NORA is a prospec-
tive study evaluating the real-life efficacy and safety of 
nivolumab in patients with advanced RCC after prior therapy. 
Estimated study completion date is October 2024. 
Numerous phase I and phase II studies, assessing the efficacy and safety of 
nivolumab in patients with RCC were identified, including FRACTION-
RCC (NCT02996110, a phase II study to test combination treatments), 
SUNIFORECAST (NCT03075423, a phase II randomised study of 
nivolumab plus ipilimumab versus standard of care in untreated and ad-
vanced non-clear-cell RCC) and BIONIKK (NCT02960906, a phase II BI-
Omarker-driven study with nivolumab and ipilimumab or vascular endothe-
lial growth factor (VEGFR) TKI in patients with naïve metastatic kidney 
cancer). Furthermore, three phase IV trials (NCT02596035, NCT02982954 
and NCT03444766), assessing the safety of nivolumab administration in ad-
vanced or metastatic RCC were found.  
 
 
 
10 Discussion 
Nivolumab (Opdivo
®
) is a human Ig4 monoclonal antibody directed against 
the negative immunoregulatory human cell surface receptor PD-1 with im-
mune checkpoint inhibitory and antineoplastic activities [3]. To date, 
nivolumab has not been approved throughout Europe for the treatment of 
patients with advanced RCC who did not receive prior treatment [8]. Since 
April 2018, nivolumab in combination with ipilimumab has been approved 
in the US for the treatment of patients with intermediate- or poor-risk ad-
vanced RCC who did not receive prior therapy [9]. Sunitinib (Sutent
®
) is a 
multiple RTK inhibitor indicated for the treatment of advanced/metastatic 
RCC in adult patients [7]. Based on results of the CheckMate 214 trial, the 
EAU [17] strongly recommends to offer ipilimumab plus nivolumab to 
treatment-naïve patients with IMDC intermediate- and poor-risk metastatic 
clear-cell RCC. 
ongoing phase I and 
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CheckMate 214, a randomised, open-label phase III study [18, 24], was con-
ducted to assess the combination of nivolumab plus ipilimumab in patients 
with previously untreated advanced RCC. Sunitinib was chosen as compara-
tor in this active controlled trial. After two formal interim analyses, inter-
mediate- and poor-risk patients who received nivolumab plus ipilimumab 
showed a statistically significant benefit in OS and ORR as compared with 
sunitinib: the 12-month OS rate was 80% versus 72%, the 18-month OS rate 
was 75% versus 60%, with a HR for death of 0.63 (99.8% CI, 0.44–0.89; p 
<0.001) and an ORR of 42% versus 27% (p <0.001) in the respective groups. 
Since crossover has been permitted as noted below, no further valid OS data 
will be available. An evaluation of HRQoL in intermediate- and poor-risk 
patients showed better results in those who were treated with nivolumab 
plus ipilimumab than in patients who received sunitinib. According to Cella 
et al. [28], additional analyses are needed to clarify the clinical importance 
of HRQoL as a potential factor to influence survival. 
Median PFS was prolonged in patients of the nivolumab-plus-ipilimumab 
group (11.6 months versus 8.4 months), whereas the between-group differ-
ence was not statistically significant. In patients of the ITT population, the 
OS benefit was also statistically significant with a HR for death of 0.68 
(99.8% CI, 0.49–0.95; p <0.001). ORR and median PFS were higher with 
nivolumab plus ipilimumab in patients of the ITT population; however, the 
differences were not statistically significant. In the subgroup of favourable-
risk patients, analyses of all endpoints favoured sunitinib.  
All patients who had quantifiable PD-L1 expression (including patients 
with less than 1% PD-L1 and 1% or greater PD-L1 expression) showed a 
prolonged OS when receiving nivolumab plus ipilimumab as compared to 
sunitinib. PFS also was prolonged among all patients with quantifiable PD-
L1 expression receiving nivolumab plus ipilimumab compared to those re-
ceiving sunitinib (PD-L1 expression <1%: +0.6 months median PFS, PD-
L1 expression ≥1%: +16.9 months median PFS); however, the gain was 
greater in patients who had 1% or greater PD-L1 expression: 22.8 months in 
nivolumab-plus-ipilimumab group patients versus 5.9 months in sunitinib 
group patients. The difference between the treatment groups with regard to 
ORR was statistically significant in patients with 1% or greater PD-L1 ex-
pression: 58% (nivolumab-plus-ipilimumab group) versus 22% (sunitinib 
group), p <0.001. 
In Germany, the median age of diagnosis of RCC is 67 years in men and 72 
years in women [13]. Hence, the age of the study population was not repre-
sentative of the actual patient population, particularly since the majority of 
study patients (265 of 425 in the nivolumab-plus-ipilimumab group and 259 
of 422 in the sunitinib group) were younger than 65 years. CheckMate 214 
subgroups including patients older than 65 years and older than 75 years 
were small, with wide CIs in OS analyses. 
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Treatment-related AEs of any grade were reported in 93% of nivolumab-
plus-ipilimumab group patients and in 97% of sunitinib group patients; 
treatment-related AEs of grade 3 or 4 occurred in 46% (nivolumab-plus-
ipilimumab group) and 63% (sunitinib group) of patients. Treatment-
related AEs leading to discontinuation of treatment were present in 22% of 
nivolumab-plus-ipilimumab group patients and in 12% of sunitinib group 
patients. Interestingly, although the rates of treatment-related AEs of any 
grade and of grade 3 or 4 were lower in patients receiving nivolumab plus 
ipilimumab, the rate of study treatment discontinuation due to treatment-
related AEs was higher among patients who received nivolumab plus ipili-
mumab. In patients receiving nivolumab plus ipilimumab, eight treatment-
related deaths occurred versus four treatment-related deaths among patients 
of the sunitinib group. Data regarding AEs were presented solely for the ITT 
population; however, AE data referring to intermediate- and poor-risk pa-
tients would have been of interest. 
PFS was used to generate the ESMO-MCBS score, since there is no form 
available to assess ORR in randomised controlled trials and due to imma-
ture OS data. Given the non-curative setting of nivolumab, we applied form 
2b of ESMO-MCBS in order to assess whether nivolumab satisfies the crite-
ria for a “meaningful clinical benefit” (score 4 or 5). Both the original as well 
as the adapted version of MCBS were applied [22, 23]. The application of 
ESMO-MCBS to the CheckMate 214 study resulted in a grade 4 in the origi-
nal and a grade 2 in the adapted version of ESMO-MCBS (see Table 3). 
Therefore, nivolumab does demonstrate a meaningful clinical benefit; how-
ever, this only applies when the original scale is used. Differences in scores 
occur due to the use of the mean estimate of effect of the HR, which is to 
avoid a systematic bias in favouring drugs with a higher degree of uncertain-
ty. 
Both external and internal validity of the CheckMate 214 trial are compro-
mised by several methodological limitations. The trial was conducted as an 
open-label study which may lead to a performance- and/or detection bias. 
Although pre-specified outcomes from the protocol, as well as withdrawal 
and reasons for discontinuations were reported, there is no AEs data of in-
termediate- and poor-risk patients available and there is a lack of CIs for 
PFS among the PD-L1 subgroups. Hence, due to the open-label setting, the 
unclear allocation concealment and additional aspects, a high risk of bias 
could be detected. Since the CheckMate 214 trial is ongoing until September 
2019, final analysis is not completed. It should be noted that a protocol 
amendment (November 2017) permitted patients from the sunitinib group 
to cross over to the nivolumab-plus-ipilimumab group after the primary 
endpoint had been met.  
Assuming an average body weight of 70 kg, 210 mg of nivolumab is needed 
for one dose of nivolumab treatment, costing € 3,432 (ex-factory price [29]), 
resulting in costs of € 13,728 for the induction phase. Based on the median 
treatment duration in the CheckMate trial of 7.9 months comprising ap-
proximately 14 doses of nivolumab, treatment costs € 48,048. Additionally, 
four doses of ipilimumab are needed (1 mg/kg every 3 weeks); based on an 
average body weight of 70 kg, 70 mg of ipilimumab is needed for one infu-
sion resulting in costs of € 34,000 for four doses. In total, costs of approxi-
mately € 82,048 for 7.9 months of combination therapy would incur. Median 
treatment duration with sunitinib was 7.8 months in CheckMate 214 trial 
patients with total costs of approximately € 26,300. Based on these calcula-
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tions, the combination treatment of nivolumab plus ipilimumab is consider-
ably more expensive than treatment with sunitinib. 
CheckMate 214 is the first phase III study investigating the efficacy and 
safety of the nivolumab-and-ipilimumab combination versus sunitinib in 
untreated patients with advanced RCC. There are results from a phase I 
study [19] indicating beneficial efficacy and safety results of nivolumab plus 
ipilimumab; however, evidence is limited due to a low sample size. General-
ly, evidence comparisons are difficult, since other studies investigating 
nivolumab plus ipilimumab were conducted in (partly heavily) pre-treated 
patients. The results of a currently ongoing (until 12/2021) phase III study 
(NCT02420821) evaluating the efficacy and safety of atezolizumab plus 
bevacizumab versus sunitinib in untreated patients with inoperable, locally 
advanced or metastatic RCC may be useful to identify the role of monoclo-
nal antibodies in this treatment setting. More data is needed to determine 
the most effective, safest and most appropriate treatment regimen for un-
treated patients with advanced RCC. 
CheckMate 214 study results show that the combination of nivolumab and 
ipilimumab provides clinical benefit in previously untreated, intermediate- 
and poor-risk patients. However, the high rate of treatment-related AEs has 
to be considered. Moreover, data regarding AEs for intermediate- and poor-
risk patients and, additionally, long-term efficacy and safety data of the 
combination therapy would be of interest. Also, it may be preferable to clari-
fy the role of monoclonal antibodies such as atezolizumab or pembroli-
zumab in this therapeutic setting. Since CheckMate 214 is the only phase III 
trial providing results of nivolumab plus ipilimumab in untreated patients 
with advanced RCC, more data is needed to evaluate this combination 
CheckMate 214: first 
phase III trial 
investigating front-line 
treatment with 
nivolumab + ipilimumab 
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Table 3: Benefit assessment based on ESMO-MCBS v1.1 and an adapted version of ESMO-MCBS [22, 23] 
ESMO-
MCBS 
Subgroup 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM MG 
months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapt-ed 
ESMO-
MCBS 
Intermediate- 
and poor-risk 
patients 
Nivolumab Advanced RCC (1st line) NC 
OS & 
ORR* 2b
2
 >6 months +3.2 
0.82  
(0.64–1.05) HR >0.65 1 
-17% grade 3–4 AEs
3
, 
+10% discontinuation 
Improved 
HRQoL 
+1
4
 
2 
Original 
ESMO-
MCBS 
Intermediate- 
and poor-risk 
patients 
Nivolumab 
Advanced RCC 
(1st line) NC 
OS & 
ORR* 2b
2 >6 months +3.2 
0.82  
(0.64–1.05) 
HR ≤0.65 AND 
gain ≥3 months 
3 x 
Improved 
HRQoL 
+1
4 
4 
Abbreviations: AEs = adverse events, AJ = adjustments, CI = confidence interval, ESMO = European Society for Medical Oncology, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, HRQoL = health-related quality of life, 
MCBS = Magnitude of Clinical Benefit Scale, MG = median gain, NC = non-curative setting, ORR = objective response rate, OS = overall survival, PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life, 
RCC = renal cell carcinoma, * co-primary endpoints 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
                                                             
2
 PFS was used to generate the ESMO-MCBS score, as there is no form available to assess ORR in randomised controlled trials and OS was not mature at the time of analysis 
3
 Data is based on the intention-to-treat population, since there are no separate results for this subgroup available 
4
 Upgrade due to an improvement in HRQoL 
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12 Appendix  
Table 4: Administration and dosing of nivolumab (Opdivo
®
) [2, 7] 
 Technology Comparator 
Administration mode Intravenous infusion (IV) Oral administration 
Description of packaging 
Opdivo® is available as a concentrate for solution 
for infusion. 
4 mL of concentrate in a 10-mL vial (Type 1 glass) 
with a stopper (coated butyl rubber) and a dark 
blue flip-off seal (aluminium). Pack size of 1 vial.  
10 mL of concentrate in a 10 mL vial (Type 1 
glass) with a stopper (coated butyl rubber) and a 
grey flip-off seal (aluminium). Pack size of 1 vial. 
Clear to opalescent, colourless to pale yellow liq-
uid that may contain few light particles. 
Sutent® 12.5 mg hard capsules (gelatin capsules with or-
ange cap and orange body, printed with white ink “Pfizer” 
on the cap, “STN 12.5 mg” on the body, and containing 
yellow to orange granules)  
Sutent® 25 mg hard capsules (gelatin capsules with cara-
mel cap and orange body, printed with white ink “Pfizer” 
on the cap, “STN 25 mg” on the body, and containing yel-
low to orange granules)  
Sutent® 37.5 mg hard capsules (gelatin capsules with yel-
low cap and yellow body, printed with black ink “Pfizer” 
on the cap, “STN 37.5 mg” on the body, and containing 
yellow to orange granules) 
Sutent® 50 mg hard capsules (gelatin capsules with car-
amel cap and caramel body, printed with white ink “Pfiz-
er” on the cap, “STN 50 mg” on the body, and containing 
yellow to orange granules) 
Total volume contained in 
packaging for sale 
Opdivo® 10 mg/mL concentrate for solution for 
infusion 
One vial of 4 mL contains 40 mg of nivolumab. 
One vial of 10 mL contains 100 mg of nivolumab. 
12.5 mg hard capsules   
25 mg hard capsules  
37.5 mg hard capsules  
50 mg hard capsules  
Dosing 
CheckMate 214 trial: Nivolumab and ipilimumab 
were administered IV at a dose of 3 mg/kg over 
60 minutes and 1 mg/kg over 30 minutes, respec-
tively, every 3 weeks for 4 doses (induction 
phase), followed by nivolumab monotherapy at a 
dose of 3 mg/kg every 2 weeks (maintenance 
phase). 
CheckMate 214 trial: Sunitinib was administered at a dose 
of 50 mg orally once daily for 4 weeks of each 6-week cy-
cle. 
Median treatment duration 
CheckMate 214 trial: Median treatment duration 
was 7.9 months in patients receiving nivolumab 
plus ipilimumab 
CheckMate 214 trial: Median treatment duration was 7.8 
months in patients receiving sunitinib. 
Contraindications 
Hypersensitivity to the active substance or to 
any of the excipients (sodium citrate dehydrate, 
sodium chloride, mannitol (E421), pentetic acid 
(diethylenetriaminepenta-acetic acid), polysorb-
ate 80, sodium hydroxide (for pH adjustment), 
hydrochloric acid (for pH adjustment), water for 
injections) 
Hypersensitivity to the active substance or to any of the 
excipients (for detailed list, see product information) 
 
Drug interactions 
Nivolumab is a human monoclonal antibody; as 
such, pharmacokinetic interaction studies have 
not been conducted. As monoclonal antibodies 
are not metabolised by cytochrome P450 (CYP) 
enzymes or other drug-metabolising enzymes, 
inhibition or induction of these enzymes by co-
administered medicinal products is not anticipat-
ed to affect the pharmacokinetics of nivolumab. 
The use of systemic corticosteroids and other 
immunosuppressants at baseline, before starting 
nivolumab administration, should be avoided be-
cause of their potential interference with the 
pharmacodynamic activity. However, systemic 
corticosteroids and other immunosuppressants 
can be used after starting nivolumab therapy to 
treat immune-related adverse reactions. The pre-
liminary results show that systemic immunosup-
pression after starting nivolumab treatment does 
not appear to preclude response to nivolumab. 
In healthy volunteers, concomitant administration of a 
single dose of sunitinib with the potent CYP3A4 inhibitor 
ketoconazole resulted in an increase of the combined 
[sunitinib + primary  
metabolite] Cmax and AUC 0- values of 49% and 51%, re-
spectively.  
 
Administration of sunitinib with potent CYP3A4 inhibi-
tors (e.g. ritonavir, itraconazole, erythromycin, clar-
ithromycin, grapefruit juice) may increase sunitinib con-
centrations.  
 
Combination with CYP3A4 inhibitors should therefore be 
avoided, or the selection of an alternate concomitant 
medicinal product with no or minimal potential to inhibit 
CYP3A4 should be considered. If this is not possible, the 
dose of Sutent® may need to be reduced to a minimum of 
37.5 mg daily for GIST and mRCC or 25 mg daily for pNET, 
based on careful monitoring of tolerability. 
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Limited clinical data are available on the interaction be-
tween sunitinib and BCRP inhibitors, and the possibility 
of an interaction between sunitinib and other BCRP in-
hibitors cannot be excluded. 
 
In healthy volunteers, concomitant administration of a 
single dose of sunitinib with the CYP3A4 inducer rifam-
picin resulted in a reduction of the combined [sunitinib + 
primary metabolite]  
Cmax and AUC0- values of 23% and 46%, respectively.  
 
Administration of sunitinib with potent CYP3A4 inducers 
(e.g. dexamethasone, phenytoin, carbamazepine, rifam-
picin, phenobarbital or herbal preparations containing St. 
John’s Wort/Hypericum perforatum) may decrease 
sunitinib concentrations. Combination with CYP3A4 in-
ducers should therefore be avoided, or selection of an al-
ternate concomitant medicinal product, with no or min-
imal potential to induce CYP3A4, should be considered. If 
this is not possible, the dose of Sutent® may need to be 
increased in 12.5 mg increments (up to 87.5 mg per day 
for GIST and mRCC or 62.5 mg per day for pNET), based 
on careful monitoring of tolerability.  
Abbreviations: AUC = area under the curve, BCRP = breast cancer resistance protein, Cmax = maximum concentration, GIST = gastrointestinal stromal tumour, 
IV = intravenous, mRCC = advanced/metastatic renal cell carcinoma, pNET = pancreatic neuroendocrine tumour 
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Table 5: Characteristics of the CheckMate 214 trial 
Title: Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma [18, 24, 25] 
Study identifier NCT02231749, EudraCT number: 2014-001750-42, CA209-214, CheckMate 214 
Design Randomised, open-label phase III trial 
Duration of main phase: Patients were randomly assigned to treatment from Octo-
ber 2014 through February 2016. 
CheckMate 214 trial is ongoing until September, 2019. 
 Median follow-up: 25.2 months 
Minimum follow-up: 17.5 months 
Hypothesis Superiority: Treatment with nivolumab combined with ipilimumab will improve PFS, OS or both 
compared to sunitinib monotherapy in patients with previously untreated mRCC. 
Funding Bristol Myers Squibb and Ono Pharmaceutical 
Treatment groups (ITT 
population) 
 
Intervention (n = 547) 
Induction phase: patients received nivolumab (3 mg/kg 
over a period of 60 minutes) and ipilimumab (1 mg/kg 
over a period of 30 minutes) IV, every 3 weeks for four 
doses. 
Maintenance phase: patients received nivolumab mono-
therapy (3 mg/kg) every two weeks. 
Control (n = 535) Patients received sunitinib at a dose of 50 mg orally once daily for four weeks of each 6-week-cycle. 
Endpoints and definitions 
 
Objective response 
rate in intermediate- 
and poor-risk patients 
(co-primary end-
point) 
 
 
ORR 
ORR was defined as the percentage of patients having a 
confirmed best response of complete response or partial 
response according to RECIST, version 1.1, on the basis of 
assessment by an independent radiology review commit-
tee. 
Progression-free sur-
vival in intermediate- 
and poor-risk patients 
(co-primary end-
point) 
PFS 
PFS was defined as the time from randomisation to first 
RECIST-defined progression or death. 
Overall survival in in-
termediate- and poor-
risk patients (co-
primary endpoint) 
OS 
 OS was defined as the time from randomisation to death. 
ORR, PFS and OS in 
the ITT population 
(secondary end-
points) 
ORR, PFS, 
OS See above. 
ORR, PFS and OS in 
favourable-risk pa-
tients (exploratory 
endpoints) 
ORR, PFS, 
OS See above. 
Level of tumour PD-
L1 level expression 
survival in intermedi-
ate- and poor-risk pa-
tients (additional ex-
ploratory endpoint) 
PD-L1 level 
This endpoint included outcomes according to the level of 
tumour PD-L1 expression (≥1% vs. <1%) as assessed at a 
central laboratory with the use of the Dako PD-L1 IHC 28-
8 pharmDx test. 
Health-related quality 
of life in intermedi-
ate- and poor-risk pa-
tients (additional ex-
ploratory endpoint) 
HRQoL HRQoL was assessed on the basis of the score on the NCCN/FACT-Kidney Symptom Index (FKSI-19). 
Database lock 7 August 2017 
Results and analysis  
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Title: Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma [18, 24, 25] 
Study identifier NCT02231749, EudraCT number: 2014-001750-42, CA209-214, CheckMate 214 
Analysis description It was estimated that 1,070 patients would undergo randomisation, with 820 having IMDC inter-
mediate or poor risk (the proportion expected according to the distribution in the general popula-
tion and the number needed for robust statistical analyses). Enrolment was discontinued once ap-
prox. 820 patients (77%) with IMDC intermediate or poor risk had undergone randomisation. The 
overall alpha level was 0.05, split among three co-primary endpoints. ORR was analysed at an al-
pha level of 0.001. PFS was evaluated at an alpha level of 0.009, with a power of 80% or more. OS 
was evaluated at an alpha level of 0.04 with 90% power (independent of co-primary endpoints) 
on the basis of a HR of 0.77, accounting for two formal interim analyses after 51% and 75% of 
deaths had occurred, using a stratified log-rank test. An O’Brien and Fleming alpha spending func-
tion was used to determine nominal significance levels that were based on the number of deaths 
for the interim and final analyses and stopping boundaries, and an adjusted alpha level of 0.002 
was used for the first interim analysis. Critical HR for the first interim analysis of OS was 0.72. 
Stratified HR between treatment groups is presented along with the 99.8% confidence interval 
(adjusted for interim analyses). For PFS, a two-sided stratified 99.1% CI for the HR was calculated. 
CIs were defined on the basis of the respective alpha level allocated to that endpoint. Estimates of 
response rate, along with the exact two-sided 95% CI by the Clopper-Pearson method were com-
puted. OS, PFS, and duration of response were estimated with the use of Kaplan-Meier methods. 
For QoL assessments, descriptive statistics and change from baseline were conducted for the FKSI-
19 score. Calculations of p-values to evaluate the between-group difference in mean change from 
baseline were based on an independent-samples t-test under the assumption that variances were 
unequal. Both a pattern-mixture model and a restricted maximum likelihood-based repeated-
measures approach were used to confirm descriptive data. 
Analysis population   
Inclusion 
 Patients aged 18 years or older 
 Previously untreated advanced RCC with a clear-cell component 
 Measureable disease according to RECIST (version 1.1) 
 Karnofsky performance status score of at least 70 (on a scale from 
0 to 100, with lower scores indicating greater disability) 
 
Exclusion 
 CNS metastases 
 Autoimmune disease 
 Use of glucocorticoids or immunosuppressants 
Characteristics of IMDC intermediate- and 
poor-risk patients 
Intervention 
(n = 425) 
Control 
(n = 422) 
Median age (range), years 62 (26–85) 61 (21–85) 
Male, n (%) 
Female, n (%) 
314 (74) 
111 (26) 
301 (71) 
121 (29) 
IMDC prognostic risk, n  
(%) 
   Favourable 
   Intermediate 
   Poor 
 
 
0 
334 (79) 
91 (21) 
 
 
0 
333 (79) 
89 (21) 
Geographic region, n (%) 
   United States 
   Canada and Europe 
   Rest of the world 
 
112 (26) 
148 (35) 
165 (39) 
 
111 (26) 
146 (35) 
165 (39) 
Quantifiable tumour PD-L1 expression,  
n/total n with evaluable data (%) 
   <1% 
   ≥1% 
 
 
284/384 (74) 
100/384 (26) 
 
 
278/392 (71) 
114/392 (29) 
Previous radiotherapy, n (%) 52 (12) 52 (12) 
Previous nephrectomy, n (%) 341 (80) 319 (76) 
Number of sites with target or nontarget le-
sions, n (%) 
   1 
   ≥2 
 
 
90 (21) 
335 (79) 
 
 
84 (20) 
337 (80) 
Most common sites of metastasis, n (%) 
   Lung 
   Lymph node 
   Bone 
   Liver 
 
294 (69) 
190 (45) 
95 (22) 
88 (21) 
 
296 (70) 
216 (51) 
97 (23) 
89 (21) 
Applicability of evidence 
Population 
The CheckMate 214 trial included patients with previously untreated advanced RCC with a clear-
cell component. The majority of ITT-population patients had IMDC intermediate or poor risk.  
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Title: Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma [18, 24, 25] 
Study identifier NCT02231749, EudraCT number: 2014-001750-42, CA209-214, CheckMate 214 
Intervention 
Participants of the CheckMate 214 trial received nivolumab 3 mg/kg over 60 minutes and ipili-
mumab 1mg/kg over 30 minutes every 3 weeks for 4 doses (induction phase), followed by 
nivolumab monotherapy 3 mg/kg every 2 weeks (maintenance phase). Except for the infusion rate, 
this dosing schedule is equal to the recommended dosage schedule approved by the FDA. 
Comparator 
Sunitinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) which is indicated for the 
treatment of advanced/metastatic RCC in adult patients. 
Outcomes 
In intermediate- and poor-risk patients treated with nivolumab plus ipilimumab, OS and ORR rates 
were significantly higher than in patients treated with sunitinib. Patients reported better HRQoL 
with nivolumab plus ipilimumab than with sunitinib. Patients generally had high rates of treat-
ment-related AEs of any grade in either group, treatment-relates AEs of grade 3 or 4 were higher 
among patients receiving sunitinib. However, the rate of discontinuation due to treatment-related 
AEs was higher in patients who received nivolumab plus ipilimumab. 
Setting 
The CheckMate 214 trial is an international study with 26% of the participants (IMDC intermedi-
ate- and poor-risk patients) from the United States, 35% from Canada and Europe and 39% of pa-
tients from the rest of the world.  
Abbreviations: CI = confidence interval, CNS = central nervous system, FACT = Functional Assessment of Cancer Therapy, FKSI = Functional 
Assessment of Cancer Therapy-Kidney Symptom Index,  HR = hazard ratio, HRQoL = health-related quality of life, IHC = 
immunohistochemistry, IMDC = International Metastatic Renal Cell Carcinoma Database Consortium, ITT = intention to treat, IV = intravenous, 
mRCC = metastatic renal cell carcinoma, n = number, NCCN = National Comprehensive Cancer Network, ORR = objective response rate, OS = 
overall survival, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, RCC = renal cell carcinoma, RECIST = Response 
Evaluation Criteria in Solid Tumors , QoL = quality of life 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (internal validity of randomised controlled trials) [20] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Patients were enrolled in the study by call-
ing an IVRS to obtain the subject number. 1:1 randomisation was performed with a block size 
of 4 with stratification according to IMDC risk score (0 vs. 1 or 2 vs. 3 to 6) and geographic re-
gion (US vs. Canada and Europe vs. the rest of the world) 
Yes 
Adequate allocation concealment Unclear 
Blinding: 
Patient: open-label No 
Treating physician: open-label No 
Selective outcome reporting unlikely: Pre-specified outcomes from the protocol were report-
ed; withdrawals and reasons for discontinuations were reported. However, there is no AEs da-
ta reported from intermediate- and poor-risk patients and there is a lack of CIs for PFS among 
the PD-L1 subgroups. 
No 
No other aspects which increase the risk of bias: The study was funded by Bristol-Myers 
Squibb and Ono Pharmaceutical. Nivolumab, ipilimumab and sunitinib were provided by the 
sponsors (except when sunitinib was procured as a local commercial product in certain coun-
tries). The trial was designed by the authors in collaboration with the sponsors. Bristol-Myers 
Squibb collected and analysed the data with the authors. Medical writing support was funded 
by Bristol-Myers Squibb. 
No 
Risk of bias – study level High 
Abbreviations: AEs = adverse events, CIs = confidence intervals, IMDC = International Metastatic Renal Cell Carcinoma Database Consor-
tium, IVRS = interactive voice response system, PD-L1 = programmed death-ligand 1, PFS = progression-free survival 
 
 
 
